Holocene Advisors LP Takes $39.16 Million Position in Abivax SA Sponsored ADR $ABVX

Holocene Advisors LP acquired a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 461,301 shares of the company’s stock, valued at approximately $39,164,000.

A number of other large investors have also recently bought and sold shares of ABVX. UBS Group AG raised its holdings in Abivax by 2,561.0% during the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after buying an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of Abivax in the third quarter worth about $263,698,000. Octagon Capital Advisors LP boosted its stake in shares of Abivax by 3.0% during the 2nd quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock worth $9,693,000 after acquiring an additional 37,000 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Abivax by 6.0% during the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock valued at $6,171,000 after acquiring an additional 56,235 shares during the last quarter. Finally, Baker BROS. Advisors LP acquired a new position in shares of Abivax during the 3rd quarter valued at about $74,355,000. 47.91% of the stock is currently owned by institutional investors.

Abivax Price Performance

NASDAQ ABVX opened at $122.75 on Tuesday. The stock has a 50-day simple moving average of $118.98 and a 200 day simple moving average of $109.39. Abivax SA Sponsored ADR has a twelve month low of $4.77 and a twelve month high of $148.83. The stock has a market capitalization of $9.71 billion, a PE ratio of -29.37 and a beta of 1.01. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86.

Abivax (NASDAQ:ABVX) last released its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The business had revenue of ($4.92) million during the quarter. Research analysts anticipate that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Wall Street Zen lowered Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Wedbush started coverage on Abivax in a report on Tuesday, February 24th. They set an “outperform” rating and a $110.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, January 21st. BTIG Research restated a “buy” rating and issued a $150.00 price objective on shares of Abivax in a research note on Wednesday, February 25th. Finally, Citizens Jmp upped their price objective on shares of Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $136.69.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.